AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05248386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-GRT7039
Description: RTX-GRT7039 intra-articular injection.
Study NCT05248386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study NCT04964063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Potassium Nitrate + Sodium Fluoride
Description: Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
Study NCT06553924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan and Tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrOpsynvi® macitentan and tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06553924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOpsynvi® macitentan and tadalafil film-coated tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study NCT06499545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release
Description: Release of pre-pressure at the latent trigger point of flexor digitorum brevis
Study NCT06499545 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non emision Laser
Description: Non emision laser in Flexor digitorum brevis latent trigger point
Study NCT06317857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centio Forte
Description: A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
Study NCT06317857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centio Forte
Description: A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
Study NCT04615962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate 1% Cream
Description: Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
Study NCT04615962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Description: Mometasone is a medium-strength corticosteroid.
Study NCT04615962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNG100
Description: A combination of low potency steroid and skin barrier repair agent
Study NCT04628806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTC isolation by HSP70
Description: patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
Study NCT05129306 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
Study NCT04946214 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smart Water Bottle
Description: Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
Study NCT04936555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
Study NCT05517603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AJ201
Description: Administered orally
Study NCT05517603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04638309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-548 + Azacitidine
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
Study NCT04456920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visit
Description: And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
Study NCT06202118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study NCT06106659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini Midline
Description: The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector.
Study NCT06106659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mini Midline
Description: The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector.
Study NCT06631365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrEPsmart mobile app
Description: The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging
Study NCT06631365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
Study NCT04895007 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine
Description: Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
Study NCT04905316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
Study NCT04905316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
Study NCT04905316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
Study NCT04905316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
Study NCT05324631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily
Study NCT05324631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo
Description: SHR0302 placebo, oral, once daily
Study NCT04518566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudges
Description: Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
Study NCT04855435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS8(1V270)
Description: The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
Study NCT05977296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: To use CPAP
Study NCT06549335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
Description: Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles.
Study NCT05849467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89 Zr-Df-crefmirlimab
Description: an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours).
Study NCT06564883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.20% sodium hyaluronate gel
Description: Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
Study NCT06637943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POC viscoelastic test
Description: applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
Study NCT06637943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: standard central laboratory test
Description: applying central laboratory test to arterial blood sample
Study NCT04789941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum + Irinotecan
Description: Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
Study NCT05744479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin oral, 2000mg/day, for 24 weeks.
Study NCT05744479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for 24 weeks
Study NCT05744479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
Study NCT05744479 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Intervention
Description: Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
Study NCT05339555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Instructions for IUD Self-Removal Provided to Participant
Description: The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
Study NCT06451146 — intervention group
Intervention type: PROCEDURE
Intervention: PCI Facilitated with Orbital Atherectomy Device
Description: Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
Study NCT05643404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
Study NCT06532760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling to study sodium fragment kinetics
Study NCT06532760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling to study sodium fragment kinetics
Study NCT06110195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
Study NCT06110195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given with radiation weekly for 7 doses.
Study NCT06110195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given with radiation weekly for 7 doses.
Study NCT06110195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
Study NCT06492356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tripolar radiofrequency therapy
Description: Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
Study NCT06492356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical treatment
Description: Twenty patients will receive medical treatment by dermatologist.
Study NCT06492356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: Twenty patients will receive medical treatment by dermatologist.
Study NCT05564325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deflectable guidewire
Description: A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
Study NCT05564325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care guidewire (different models may be used)
Description: The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
Study NCT06328946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
Study NCT06328946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
Study NCT06328946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.